- ISIN
- US73935X8561
- CUSIP
- 46137V787
- Issuer
- Invesco
- Inception Date
- Jun 23, 2005
- Region
- North America (U.S.)
- Category
- Health & Biotech Equities
- Leveraged
- 1x (No leverage)
- Index Tracked
- Dynamic Biotech & Genome Intellidex Index (AMEX)
- Distribution Policy
- Distributing
- Asset Class
- Equity
- Asset Class Size
- Multi-Cap
- Asset Class Style
- Growth
- Assets Under Management
- $261M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
PBE Performance Chart
Invesco Dynamic Biotechnology & Genome ETF (PBE) is up 4.3% since the beginning of the year. PBE is currently trading at $85 per share. Investors who bought $1,000 worth of PBE shares 5 years ago would now be looking at an investment worth $1,117.
Loading charts...
Returns By Period
Invesco Dynamic Biotechnology & Genome ETF (PBE) has returned 4.26% so far this year and 35.92% over the past 12 months. Over the last ten years, PBE has returned 9.35% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
Invesco Dynamic Biotechnology & Genome ETF
- 1D
- 1.08%
- 1M
- 4.15%
- YTD
- 4.26%
- 6M
- 2.94%
- 1Y
- 35.92%
- 3Y*
- 12.04%
- 5Y*
- 2.24%
- 10Y*
- 9.35%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
PBE Monthly Returns History
Based on dividend-adjusted daily data since Jun 23, 2005, PBE's average daily return is +0.05%, while the average monthly return is +0.90%. At this rate, an investment would double in approximately 6.4 years.
Historically, 57% of months were positive and 43% were negative. The best month was Jul 2008 with a return of +15.7%, while the worst month was Jan 2016 at -23.7%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 5 months.
On a daily basis, PBE closed higher 51% of trading days. The best single day was May 6, 2010 with a return of +34.8%, while the worst single day was May 7, 2010 at -31.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.34% | 0.13% | -3.31% | 0.51% | 5.31% | 2.09% | 4.26% | ||||||
| 2025 | 4.26% | -3.82% | -4.86% | -1.83% | 0.53% | 2.59% | 1.87% | 4.82% | 2.41% | 7.10% | 11.35% | -0.91% | 24.84% |
| 2024 | -2.32% | 1.95% | -1.25% | -5.94% | 3.98% | 2.42% | 8.26% | 2.43% | -2.85% | -2.32% | 3.37% | -5.63% | 1.10% |
| 2023 | 5.17% | -4.73% | -1.34% | -0.28% | -3.67% | 1.66% | 3.53% | -2.98% | -7.35% | -6.04% | 9.34% | 12.36% | 3.71% |
| 2022 | -14.72% | -0.76% | 2.92% | -9.33% | 1.26% | 1.39% | 5.68% | -0.89% | -2.55% | 7.62% | 5.03% | -4.69% | -10.83% |
| 2021 | 7.92% | -2.00% | -0.47% | 2.17% | -2.92% | 5.61% | -2.50% | 4.10% | -4.65% | 0.31% | -6.10% | 1.03% | 1.54% |
Benchmark Metrics
Invesco Dynamic Biotechnology & Genome ETF has an annualized alpha of 2.67%, beta of 0.92, and R2 of 0.42 versus S&P 500 Index. Calculated based on daily prices since June 23, 2005.
- R2 of 0.42 means the benchmark explains less than half of this ETF's behavior - treat beta with caution or consider switching to a more representative benchmark.
- Alpha
- 2.67%
- Beta
- 0.92
- R²
- 0.42
- Upside Capture
- 101.52%
- Downside Capture
- 102.07%
Expense Ratio
PBE has an expense ratio of 0.59%, placing it in the medium range.
Return for Risk
Risk / Return Rank
PBE ranks 58 for risk / return — on par with similar ETFs. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Invesco Dynamic Biotechnology & Genome ETF (PBE) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PBE | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.13 | ||
| Sortino ratioReturn per unit of downside risk | +0.05 | ||
| Omega ratioGain probability vs. loss probability | 1.32 | 1.37 | -0.04 |
| Calmar ratioReturn relative to maximum drawdown | 3.08 | 2.78 | +0.29 |
| Martin ratioReturn relative to average drawdown | 8.64 | 12.44 | -3.80 |
Dividends
Dividend History
Invesco Dynamic Biotechnology & Genome ETF provided a 1.98% dividend yield over the last twelve months, with an annual payout of $1.68 per share. The fund has been increasing its distributions for 2 consecutive years.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $1.68 | $0.82 | $0.03 | $0.01 | $0.00 | $0.00 | $0.03 | $0.00 | $0.00 | $0.27 | $0.15 | $0.57 |
Dividend yield | 1.98% | 1.00% | 0.05% | 0.02% | 0.00% | 0.00% | 0.04% | 0.00% | 0.00% | 0.57% | 0.38% | 1.12% |
Monthly Dividends
The table displays the monthly dividend distributions for Invesco Dynamic Biotechnology & Genome ETF. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $0.00 | $0.08 | $0.00 | $0.00 | $0.81 | $0.89 | ||||||
| 2025 | $0.00 | $0.00 | $0.03 | $0.00 | $0.00 | $0.13 | $0.00 | $0.00 | $0.23 | $0.00 | $0.00 | $0.42 | $0.82 |
| 2024 | $0.00 | $0.00 | $0.02 | $0.00 | $0.00 | $0.01 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.03 |
| 2023 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.01 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.01 |
| 2022 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2021 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Invesco Dynamic Biotechnology & Genome ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Invesco Dynamic Biotechnology & Genome ETF was 45.69%, occurring on Mar 9, 2009. Recovery took 293 trading sessions.
The current Invesco Dynamic Biotechnology & Genome ETF drawdown is 0.10%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Financial crisis2007–2009 | -45.69%Mar 2009 | 1y 4mo | 1y 1mo | 2y 6moOct 2007 - May 2010 |
2016 bear market2016 | -44.56%Jun 2016 | 11mo 13d | 4y 24d | 5y 2dJul 2015 - Jul 2020 |
Bear market2022 | -37.84%Jun 2022 | 1y 4mo | 3y 5mo | 4y 9moFeb 2021 - Nov 2025 |
2010 bear market2010 | -35.71%Jul 2010 | 2mo | 2y 9mo | 2y 11moMay 2010 - Apr 2013 |
2006 bear market2006 | -21.12%Jul 2006 | 4mo 19d | 9mo 10d | 1y 1moFeb 2006 - Apr 2007 |
Drawdown Indicators
| PBE | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -45.69% | -56.78% | +11.09% |
Max Drawdown (1Y)Largest decline over 1 year | -11.73% | -9.10% | -2.63% |
Max Drawdown (3Y)Largest decline over 3 years | -22.43% | -18.90% | -3.53% |
Max Drawdown (5Y)Largest decline over 5 years | -34.71% | -25.43% | -9.28% |
Max Drawdown (10Y)Largest decline over 10 years | -37.84% | -33.92% | -3.92% |
Current DrawdownCurrent decline from peak | -0.10% | -1.80% | +1.70% |
Average DrawdownAverage peak-to-trough decline | -16.20% | -10.71% | -5.49% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.17% | 2.03% | +2.14% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Build a portfolio with PBE
Add Invesco Dynamic Biotechnology & Genome ETF to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with PBE